DUBLIN, July 28,
2022 /PRNewswire/ -- Theravance Biopharma, Inc.
(NASDAQ: TBPH) will report its second quarter 2022 financial
results and provide a business update after market close on
Thursday, August 4, 2022. An
accompanying conference call and simultaneous webcast will be
hosted at 5:00 pm ET (2:00 pm PT/10:00 pm
IST) that day.
Conference Call Information
To participate in the live call by telephone, please dial (800)
225-9448 from the US or (203) 518-9708 for international callers,
using the conference code TBPHQ222. Those interested in listening
to the conference call live via the internet may do so by visiting
Theravance Biopharma's website at www.theravance.com, under the
Investors section, Presentations and Events.
A replay of the conference call will be available on Theravance
Biopharma's website for 30 days through September 3, 2022. An audio replay will also be
available through 11:59 pm ET on
August 11, 2022 by dialing (888)
219-1261 from the US, or (402) 220-4941 for international
About Theravance Biopharma
Theravance Biopharma, Inc.'s overarching purpose and goal as a
biopharmaceutical company is focused on delivering Medicines
that Make a Difference® in people's lives. In
pursuit of its purpose, Theravance Biopharma leverages decades of
expertise, which has led to the development of FDA-approved
YUPELRI® (revefenacin) inhalation solution indicated for
the maintenance treatment of patients with chronic obstructive
pulmonary disease (COPD). Its pipeline of internally discovered
programs is targeted to address significant unmet patient
needs. For more information, please
THERAVANCE BIOPHARMA®, THERAVANCE®, and
the Cross/Star logo are registered trademarks of
the Theravance Biopharma group of companies (in
the U.S. and certain other countries).
YUPELRI® is a registered trademark of Mylan
Specialty L.P., a Viatris Company. Trademarks, trade names or
service marks of other companies appearing on this press release
are the property of their respective owners.
Contact: Gail B. Cohen
Corporate Communications / 917-214-6603
View original content to download
SOURCE Theravance Biopharma, Inc.